• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Reducing the Risk of Comparator Sourcing

    Clinical Data Management

    Leveraging AI/ML Analytics for Better Clinical Development Decisions

    What is a Manufacturing Ecosystem and Why are They Growing?

    Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins

    RK Pharma to Receive $200M Investment from PAG

    Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

    TMC Expands Executive Team

    Peli BioThermal Opens Cold Chain Network Station in Southern California
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins

    RK Pharma to Receive $200M Investment from PAG

    Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

    Peli BioThermal Opens Cold Chain Network Station in Southern California

    Purolite Expands Bioprocessing Production Capacity with New U.S. Facility
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Peli BioThermal Opens Cold Chain Network Station in Southern California

    Biocair Partners with TrakCel to Improve Visibility in the Supply Chain

    SpectronRx, RLS Partner to Boost Radiopharmaceutical Pipeline and Supply Chain

    Serialization and the War on Counterfeit Drugs

    Traceability & 2D Barcodes
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    RK Pharma to Receive $200M Investment from PAG

    Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

    Almac Group Global Workforce Hits 7,000 Employees

    Amarna Therapeutics Names Henk Streefkerk CEO

    Trinity Life Sciences Names Leslie Orne CEO
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Regulatory Affairs: Accelerating Drug Development Timelines

    Berkshire Sterile Secures Over $230,000 in Training Grants

    Purification – A Bottleneck for Large-Scale Manufacturing of Oligonucleotide API?

    FDA 2023 Inspection Roadmap: Is “Readiness” in Your Annual Objectives?

    FDA Watch: Are You Suitably Staffed?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Almac Group

    U.S. Pharmacopeia (USP)

    TaiMed Biologics

    LOTTE BIOLOGICS

    INCOG BioPharma Services
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Almac Group

    U.S. Pharmacopeia (USP)

    TaiMed Biologics

    LOTTE BIOLOGICS

    INCOG BioPharma Services
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Top Companies Report

    12 AstraZeneca

    ...

    12	AstraZeneca
    07.20.18
    Headquarters: London, UK
    twitter.com/astrazeneca
    www.astrazeneca.com

    Headcount: 61,100
    Year Established:  1999
    Revenues:  $22,465  (-2%)
    Net Income:  $2,868  (-16%)
    R&D: $5,757  (-2%)

    TOP SELLING DRUGS   
    Drug Indication 2017 Sales (+/-%)
    Symbicort asthma $2,803 -6%
    Crestor cholesterol $2,365 -30%
    Nexium acid reflux $1,952 -4%
    Pulmicort asthma $1,176 11%
    Brilinta  antiplatelet  $1,079 29%
    Farxiga type 2 diabetes $1,074 29%
    Tagrisso lung cancer $955 126%
    Faslodex breast cancer $941 13%
    Zoladex cancer $735 -10%
    Seloken/Toprol-XL hypertention $695 -6%
    Synagis RSV disease $687 1%

    While revenue was down for the year, AstraZeneca appears to be finally emerging from several years of declining sales. Between 2011 and 2017, the company saw more than $13 billion in lost revenue in established markets for its top selling drugs and expects to lose a further $1 billion in product sales. There’s no doubt the company faces continued challenges with strong competition from both branded and generic medicines, but product sales were up 4% in the fourth quarter of 2017, and 3% in the first quarter of 2018, and long-term prospects remain encouraging. Additionally, Brilinta and Farxiga each exceeded $1 billion in annual sales for the first time.

    Newer products, Imfinzi for cancer and Fasenra for severe asthma, both performed well in 1Q18. Oncology sales saw growth of 39%, with Lynparza sales up 109% to $119 million, driven by regulatory approvals in the U.S.; Tagrisso sales grew 98% to $338 million; and Imfinzi sales reached $62 million as a result of the recent U.S. approval for stage III non-small cell lung cancer (NSCLC). Needless to say, this impressive growth was offset by the decline of Crestor sales in Europe and Japan.

    AZ launched four new molecular entities in 2017, including its first respiratory biologic medicine, Fasenra and new cancer medicines, Imfinzi and Calquence. Additionally, key existing treatments Lynparza and Tagrisso gained new indications.

    AZ and its global biologics R&D arm, MedImmune, won approval of Fasenra (benralizumab) in the U.S. and EU as an add-on maintenance treatment in severe eosinophilic asthma. They also gained FDA approval of Imfinzi for the treatment unresectable Stage III NSCLC, representing the company’s first immuno-oncology approval. Imfinzi is in development across several tumor types, both as monotherapy and with other medicines, and received accelerated approval from the FDA in May for the treatment of advanced bladder cancer. Also, in a recent trial, Imfinzi demonstrated superior progression-free survival (PFS) in NSCLC.

    Additional oncology wins include expanded approval for Tagrisso for patients with newly diagnosed, EGFR-positive NSCLC based on results that showed significant PFS benefit (18.9 months versus 10.2 months) compared with standard of care. This past year, Tagrisso became AZ’s highest-selling oncology drug with sales of $955 million (up 126%), and, by the end of 2017, received regulatory approval in more than 60 countries. 

    AZ and partner Merck gained approval of Lynparza in Japan for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer, regardless of BRCA mutation status. Lynparza is the first poly ADP-ribose polymerase (PARP) inhibitor to be approved in Japan.

    Also, AZ and Acerta Pharma won approval of Calquence (acalabrutinib), a kinase inhibitor for the treatment of mantle cell lymphoma. Calquence was approved under the FDA’s accelerated approval pathway, based on overall response rate.

    Moreover, the FDA recently approved Lokelma (sodium zirconium cyclosilicate), formerly ZS-9, for the treatment of hyperkalaemia, a serious condition characterized by high potassium levels in the blood associated with cardiovascular, renal and metabolic diseases. The risk of hyperkalaemia increases significantly for patients with chronic kidney disease and for those who take common medications for heart failure.

    In a blow to its late stage pipeline, AZ and Lilly recently discontinued the global Phase III trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor, for the treatment of Alzheimer’s disease (AD). The decision was based on recommendations by an independent data monitoring committee, which concluded that the trials in early and mild AD dementia were not likely to meet their primary endpoints. 

    The company executed a several strategic ventures this past year, namely MedImmune’s spin out of six molecules from its early-stage inflammation and autoimmunity programs into an independent biotech company, Viela Bio. The new company will focus on medicines for severe autoimmune diseases by targeting the underlying causes of each disease.  
      
    MedImmune will contribute three clinical and three preclinical candidates, including inebilizumab, currently in Phase II development for the treatment of neuromyelitis optica, a rare condition that affects the optic nerve and spinal cord. It was granted Orphan Drug Designation in the U.S. and Europe. The transaction doesn’t include anifrolumab, in Phase III development for the treatment of lupus.

    AZ also entered a strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to form an equally-owned, stand-alone company in China to develop and commercialize potential new medicines with the goal of accelerating development efforts. The new company, Dizal Pharmaceutical, has access to the scientific and technical capabilities of AZ’s Innovation Center China, and has exclusive rights to develop and commercialize three preclinical candidates from AZ’s pipeline in the areas of oncology, cardiovascular and metabolic diseases, and respiratory. The FIIF will contribute funding and arrange strategic partnerships.

    Additionally, several collaborations from this past year are proving successful. For example, AZ’s global strategic oncology alliance with Merck to co-develop and co-commercialize Lynparza for multiple cancer types. Lynparza is a first-in-class oral PARP inhibitor, and in addition to current indications in breast and ovarian cancer, Lynparza is also being developed across several tumor types, including prostate and pancreatic cancers. The companies are developing Lynparza both as monotherapy and in combination with other potential medicines. The companies are also developing AZ’s selumetinib, a selective inhibitor of MEK, for multiple indications including thyroid cancer.

    AZ’s clinical collaboration with Incyte Corp. is also advancing. The alliance was expanded to evaluate the efficacy and safety of epacadostat, Incyte’s investigational IDO1 enzyme inhibitor, in combination with AZ’s Imfinzi, a human monoclonal antibody directed against PD-L1, compared to Imfinzi alone. The exclusive collaboration allows the companies to conduct a Phase III trial in patients with Stage III NSCLC whose disease has not progressed following chemotherapy and radiation therapy. 

    Finally, another endeavor with Takeda aims to develop MEDI1341, an alpha-synuclein antibody as a potential treatment for Parkinson’s disease (PD). The companies aim to support the development of new PD medicines that seek to remove existing pathological alpha-synuclein aggregates, prevent their formation, or stop them from spreading, and as such potentially prevent or delay the onset of PD, or halt or slow its progression.

    With these efforts, sales growth of new drugs, and an advancing pipeline, AZ is on track for a period of recovery in 2018. 
    Related Searches
    • biologics
    • immuno-oncology
    • biotech
    • Development
    Suggested For You
    NuvOx Completes Construction of Expanded Manufacturing Facility NuvOx Completes Construction of Expanded Manufacturing Facility
    January 2021: Auction of BioPharma Lab Equipment From Icagen January 2021: Auction of BioPharma Lab Equipment From Icagen
    05	Merck 05 Merck
    10	Lilly 10 Lilly
    Takeda, Ovid Detail Clinical Development Program Takeda, Ovid Detail Clinical Development Program
    Takeda Selects leon-nanodrugs’s MicroJet Reactor for Feasibility Takeda Selects leon-nanodrugs’s MicroJet Reactor for Feasibility
    Bicycle Therapeutics, AstraZeneca Expand Collaboration Bicycle Therapeutics, AstraZeneca Expand Collaboration
    DPS Group Wins Contract in Sweden from AstraZeneca DPS Group Wins Contract in Sweden from AstraZeneca
    Lilly to Acquire Armo BioSciences for $1.6B Lilly to Acquire Armo BioSciences for $1.6B
    Takeda to Acquire Shire in $62B Deal Takeda to Acquire Shire in $62B Deal
    Ionis Licenses NASH Drug to AstraZeneca Ionis Licenses NASH Drug to AstraZeneca
    Rhythm, Takeda Enter Development Agreement Rhythm, Takeda Enter Development Agreement
    Integrated Early-Stage Drug Development and Manufacturing Integrated Early-Stage Drug Development and Manufacturing
    Saudi-SPIMACO and AstraZeneca Sign MOU Saudi-SPIMACO and AstraZeneca Sign MOU
    Beacon Discovery, Takeda Partner for Drug Discovery Beacon Discovery, Takeda Partner for Drug Discovery

    Related Breaking News

    • Bio News | Breaking News | Facilities | Industry News
      NuvOx Completes Construction of Expanded Manufacturing Facility

      NuvOx Completes Construction of Expanded Manufacturing Facility

      Will manufacture its lead product, NanO2, for clinical trials and commercial supply after FDA approval.
      Tim Wright, Editor, Contract Pharma 05.03.21

    • January 2021: Auction of BioPharma Lab Equipment From Icagen

      ...

    • 05	Merck

      05 Merck

      ...
      07.20.18


    • 10	Lilly

      10 Lilly

      ...
      07.20.18

    • Clinical Trials | Collaborations & Alliances | Industry News | R&D
      Takeda, Ovid Detail Clinical Development Program

      Takeda, Ovid Detail Clinical Development Program

      The companies plan to initiate three clinical trials to investigate the potential of TAK-935/OV935
      07.18.18

    Loading, Please Wait..
    Trending
    • SpectronRx, RLS Partner To Boost Radiopharmaceutical Pipeline And Supply Chain
    • Samsung Biologics Accelerates Timeline Of New Fifth Plant
    • Biopharma Layoffs In 1Q23
    • Veeva Business Consulting Expands With New R&D Services
    • CRO Industry Trends & Challenges
    Breaking News
    • EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins
    • RK Pharma to Receive $200M Investment from PAG
    • Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease
    • TMC Expands Executive Team
    • Peli BioThermal Opens Cold Chain Network Station in Southern California
    View Breaking News >
    CURRENT ISSUE

    May 2023

    • New Modalities Hog the Limelight
    • Cell and Gene Therapy is Coming of Age
    • Demand Surges for Cell and Gene Therapy Contract Manufacturing
    • Embracing a New Reality
    • Japan: A Unique Opportunity for Regenerative Medicines and Cell & Gene Therapies
    • Single-Use Technologies Enable Biologic Scaling
    • Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    • FTEs in Drug Discovery
    • Digital Transformation in Pharma
    • What is a Manufacturing Ecosystem and Why are They Growing?
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Sempera Organics and Alkemist Labs Announce Partnership for Mushroom Testing
    Nektium Expands International Distribution Network for Botanical Extracts
    Kemin Receives Positive EFSA Opinion for BetaVia Pure, its Beta-Glucan Ingredient
    Coatings World

    Latest Breaking News From Coatings World

    PPG’s New Paint for a New Start Initiative to Beautify Schools Worldwide with Colorful Makeovers
    Powder Technology, Inc. Announces New Electrical Coating
    Michelman Chosen as Inaugural Recipient of Innovation Research Interchange (IRI) Excellence Award
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cue Health Nabs FDA's First De Novo Nod for an At-Home COVID Test
    ISO 13485:2016 Certification Granted to Boston BioProducts
    Paul Colvin Joins Ora Inc. as Chief Operating Officer
    Contract Pharma

    Latest Breaking News From Contract Pharma

    EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins
    RK Pharma to Receive $200M Investment from PAG
    Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Estée Lauder Announces Second Edition of Beauty&You Brand Incubator Program
    GetHarley Raises $52 Million in Latest Funding Round
    Refillable Skincare Products Face Hurdles Despite Growing Sustainability Awareness
    Happi

    Latest Breaking News From Happi

    Carrière Frères Introduces Candle Refills as New Sustainability Initiative
    Gen Z Entrepreneur Introduces The Ashley Marie Collection for 4C Hair Types
    The Estée Lauder Companies Expands Beauty&You Competition for Indian Beauty Brands
    Ink World

    Latest Breaking News From Ink World

    Siegwerk’s Center of Excellence in France Receives Facelift
    Epson announces MakeTheSwitch Campaign
    Pigments Market to Reach $26,598 Million by 2022: AMR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Mark Andy reports successful Low Migration Workshop
    Ryback and Ryback Consulting launches Machinery division
    TLMI launches 2023 award programs
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    The Honest Company to Exit Europe, Asia
    TechnoPlants to Exhibit at ITMA
    Andritz Buys 100% Stake in Dan-Web
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Orthobiologics Market to Top $10.3 Billion by 2030
    Artelon Granted U.S. FDA 510(k) Clearance for FlexBand, FlexPatch & FlexBand Plus
    Synergy Spine Solutions Completes Enrollment in IDE Clinical Trial
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    ASSA ABLOY Receives Clearance from Mexico for HHI Acquisition
    Christoph Ostermann Named Chairman of Heliatek‘s Advisory Board
    Flexible and Printed Electronics Represented at productronica 2023

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login